Skip to main content
Numero verde Huntington
info@lirh.it
| Toll-free number
800 388 330
800 388 330
EN
Toggle Dropdown
EN
IT
Huntington's Disease
What is HD
Symptoms of Huntington’s Disease
How to treat the disease
Genetic testing
Huntington e genitorialità
Huntington’s Disease in children
History of Huntington’s Disease
HD Patient Journey
Italian White Paper on Huntington's Disease
Huntington's Disease management model
Who we are
LIRH Foundation
Our people
Our network
Our Team
What we do
Research
Care
Awareness
Annual Conference
Get involved
Make a Donation
5xmille
Participate
Become a member
Solidary favors
Corporate donations
Clinical Trials
Why participate
Testimonies
News & media
Latest news
Video
Events
Media Kit
Huntington Post
Webinar
Contacts
Where to find us
Questions and answers
Ask to expert
Get in touch
Careers
Menu
Home
Latest news
Huntington's disease: Tominersen dosing interruption in Generation HD1 - Questions and Answers
Si interrompe la somministrazione di tominersen nella sperimentazione Generation HD1 di Roche per la malattia di Huntington
Huntington Disease (HD): Let’s color our voices! - Rare Disease Day 2021
Updates on AMT-130 gene therapy for the treatment of Huntington's disease
A common neurodegeneration marker for Huntington's, Parkinson's, and Alzheimer's disease
The first European patients in the Phase 3 'Proof-HD' trial with Pridopidine in Huntington's disease are from Italy and Germany
Healthe-RND: Toward a telemedicine model for Huntington's and rare neurodegenerative diseases
LIRH Annual Conference 2020: The Current treatment Perspectives for Huntington Disease
World (dis)ability Day 2020
PTC Therapeutics has started in-human Huntington’s disease trial with PTC518
The emotions' recognition and the adequacy of visual scanning in a recent study on pre-manifest HD
Huntington’s Disease: Prilenia Enrolls First Patients into PROOF-HD Clinical Trial
Treatment for SMA could be used for Huntington’s disease: new trial planned for next year
Huntington Disease: other two Patients Treated in the AMT-130 Trial
SIGNAL trial: pepinemab does not affect Huntington disease's symptoms
Conect4children: A network for European clinical trials for children
Huntington's disease: evidence of altered brain development even before birth
The first Epidemiological study on Huntington in the Middle East makes the rethinking of the global number of people affected by HD necessary
The origin of Huntington Disease in the Middle East described for the very first time: Why this is relevant for possible future treatments
UniQure Announces First Two Patients Treated in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
Let's meet Pantaleone Megna, director of the "The Shape of Life"
A new hope for a cure: pridopidine will return to a experimental phase
What we learnt by providing assistance to Huntington families during the Coronavirus’ emergency
Pagination
First page
« First
Previous page
‹‹
Page
1
Current page
2
Page
3
Next page
››
Last page
Last »
Everything is possible, if we are many!
DONATE
GET INVOLVED
5x1000
1
1
Huntington's Disease
What is HD
Symptoms of Huntington’s Disease
How to treat the disease
Genetic testing
Huntington e genitorialità
Huntington’s Disease in children
History of Huntington’s Disease
HD Patient Journey
Italian White Paper on Huntington's Disease
Huntington's Disease management model
Who we are
LIRH Foundation
Our people
Our network
Our Team
What we do
Research
Care
Awareness
Annual Conference
Get involved
Make a Donation
5xmille
Participate
Become a member
Solidary favors
Corporate donations
Clinical Trials
Why participate
Testimonies
News & media
Latest news
Video
Events
Media Kit
Huntington Post
Webinar
Contacts
Where to find us
Questions and answers
Ask to expert
Get in touch
Careers